nab-paclitaxel-based therapy in underserved patient populations: The ABOUND.PS2 study in patients with NSCLC and a performance status of 2

Ajeet Gajra, Nagla Abdel Karim, Deborah A. Mulford, Liza Cosca Villaruz, Marc Ryan Matrana, Haythem Y. Ali, Edgardo S. Santos, Tymara Berry, Teng Jin Ong, Alexandra Sanford, Katayoun Amiri, David R. Spigel

Research output: Contribution to journalArticle

4 Scopus citations

Abstract

Introduction: The phase II ABOUND.PS2 study (NCT02289456) assessed safety/tolerability of a first-line modified nab-paclitaxel/carboplatin regimen for patients with advanced non-small cell lung cancer (NSCLC) and Eastern Cooperative Oncology Group (ECOG) performance status (PS) 2. Methods: Chemotherapy-naive patients with stage IIIB/IV NSCLC and ECOG PS 2 received four cycles of nab-paclitaxel 100 mg/m2 days 1 and 8 plus carboplatin area under the curve 5 day 1 q3w (induction). Patients without progression received nab-paclitaxel monotherapy (100 mg/m2 days 1 and 8 q3w) until progression/unacceptable toxicity. Primary endpoint: percentage of patients discontinuing induction due to treatment-emergent adverse events (TEAEs). Results: 11/40 treated patients (27.5%; 95% CI, 14.60-43.89) discontinued chemotherapy induction due to TEAEs; 16/40 (40.0%) continued nab-paclitaxel monotherapy. Median progression-free and overall survival were 4.4 (95% CI, 2.99-7.00) and 7.7 (95% CI, 4.93-13.17) months. Grade 3/4 TEAEs during induction included neutropenia (22.5%), anemia (17.5%), thrombocytopenia (5.0%), and peripheral neuropathy (2.5%). Conclusion: This nab-paclitaxel-based regimen was tolerable in patients with advanced NSCLC and ECOG PS 2, with efficacy comparable to historical chemotherapy data.

Original languageEnglish (US)
Article number253
JournalFrontiers in Oncology
Volume8
Issue numberJUL
DOIs
StatePublished - Jul 24 2018

Keywords

  • Chemotherapy
  • Maintenance therapy
  • Nab-paclitaxel
  • Non-small cell lung cancer
  • Poor performance status

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'nab-paclitaxel-based therapy in underserved patient populations: The ABOUND.PS2 study in patients with NSCLC and a performance status of 2'. Together they form a unique fingerprint.

  • Cite this

    Gajra, A., Karim, N. A., Mulford, D. A., Villaruz, L. C., Matrana, M. R., Ali, H. Y., Santos, E. S., Berry, T., Ong, T. J., Sanford, A., Amiri, K., & Spigel, D. R. (2018). nab-paclitaxel-based therapy in underserved patient populations: The ABOUND.PS2 study in patients with NSCLC and a performance status of 2. Frontiers in Oncology, 8(JUL), [253]. https://doi.org/10.3389/fonc.2018.00253